Abstract: Three weeks after the administration of intravenous methylprednisolone therapy, a 42-year-old female patient suffering from relapsing-remitting multiple sclerosis (RR-MS) presented with a profound elevation of liver transaminases (GOT 485 U/l, GPT 1082 U/l, glutamyl transpeptidase 170 U/l). Liver biopsy revealed a profound, still active hepatitis with portal lymphocytic infiltration and fibrosis. Most likely, existing acute hepatitis was of autoimmune origin and emerged from an immune rebound phenomenon after immunosuppressive therapy.
Introduction
Multiple Sclerosis is the most prevalent neurological disease with regard to sustained disability and premature retirement in young adults. At the onset of natural history, the relapsing-remitting disease course prevails. Intravenous methylprednisolone pulse therapy (MPT) is the standard treatment for relapse. Hitherto, there is only one single report on acute hepatitis related to high-dose methylprednisolone therapy in a 46-year-old female RR-MS patient that presented with repeated episodes of elevated liver enzymes [1] . In this case, diagnosis was made based on serum chemistry analysis, but a pathological analysis including a liver biopsy had not been performed and thus the etiology was not established.
Case report
A 42-year-old female patient suffering from relapsing-remitting multiple sclerosis (RR-MS) presented with a slight increase in leukocytes and lactat-dehydrogenase, alkaline phosphatase, amylase and c-reactive protein, and a profound elevation of liver transaminases (GOT 485 U/l (normal range 10 -35 U/l), GPT 1082 U/l (normal range 10 -35 U/l), glutamyl transpeptidase 170 U/l (normal range 5 -39 U/l)). The patient refrained from taking hepatotoxic drugs and denied any drinking of alcoholic beverages. Eight months ago, the second relapse with paresis of the right leg in combination with typical results in MRI and oligoclonal bands in cerebrospinal fluid (CSF) had led to the diagnosis of MS according to McDonald (2001) . Interferon beta and other immunomodulatory or immunosuppressive drugs had not been prescribed. At that time, laboratory values had been normal, for example with regard to liver enzymes. Ten weeks ago, an intravenous MPT for relapse brought about only a marginal recovery and three weeks ago, a second high-dose MPT produced a distinct remission (cumulative five grams, respectively).
Neurological examination revealed a mild depression, bilaterally reduced visual acuity, right-sided accentuation of reflexes, ataxia of the right leg and gait ataxia. Expanded disability status scale (EDSS) was 2.0. Virology for hepatitis A, B and C, HSV and CMV were negative. There was no acute EBV infection. One week later, abdominal sonography was normal except for confirmation of an intrauterine pregnancy with fetal length of 1.9 cm. Thyroid gland sonography and abdominal MRI were normal. Pregnancy was terminated within five weeks. General symptomatic measures were taken including physical resting, a low-fat diet and abandonment of alcohol. Ten weeks later, a liver biopsy revealed a profound, still active hepatitis with portal lymphocytic infiltration and fibrosis ( Figure 1 ). During these ten weeks, GOT and GPT decreased to 100 or 140 U/l, while cholestasis parameters (alkaline phosphatase, glutamyl transpeptidase and bilirubin) increased.
Discussion
Liver biopsy and serum chemistry analysis revealed a profound, still active hepatitis with portal lymphocytic infiltration and fibrosis. As comprehensive diagnostic investigation didn't yield another definite reason, the existing acute hepatitis was most likely of autoimmune origin.
The prevalence of autoimmune hepatitis (AIH) is about 0.017% in the general population and seems to be about ten times higher in MS patients, which raises the question whether or not humoral mechanisms play an important role in the association of these two diseases [2] . Administration of interferon beta is currently standard immunomodula-tory therapy for RR-MS. It can produce hepatitis that should decline after withdrawal of the drug. If a sustained serum level of liver enzymes is still observed, an AIH screening should be performed. In a single case, AIH was found after interferon beta treatment for MS [3] . Particularly, AIH might occur in patients with multiple autoimmunity as an immune rebound phenomenon after immunosuppressive therapy regimens, as shown in two cases of patients with Hashimoto's thyreoditis [4] or Graves' ophthalmopathy [5] receiving MPT. Administration of corticosteroids might restore immunosuppression.
